Silexion Therapeutics (SLXN) Gets a Buy from Maxim Group
In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...
bovnews14h
Silexion Therapeutics Corp (SLXN) Stock: A Deeper Look at Its True Potential
Silexion Therapeutics Corp’s profitability metrics reveal financial health. The company currently boasts a gross margin of -97.05%. The profit margin, also known as the revenue ratio or gross profit ...
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...
Silexion reports breakthrough in KRAS cancer therapy
CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced ...
Stocktwits on MSN14d
Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures
Shares of Silexion Therapeutics lost more than a quarter of their market capitalization on Thursday morning, hitting a record intraday low after the company priced a $5 million public offering late ...
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday?
Silexion Therapeutics shares preclinical data on SIL-204, highlighting tumor reduction in KRAS-driven cancers and sustained drug efficacy for 56+ days.
Silexion Therapeutics reports preclinical data for SIL-204
Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...
Nasdaq17d
Silexion Therapeutics to Present at 2025 ASCO Gastrointestinal Cancers Symposium on Innovative RNAi Therapy for KRAS-Driven Cancers
Silexion Therapeutics Corp. announced that it will present a poster at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco, scheduled for January 23-25, 2025. The presentation will ...
Morningstar15d
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...
Nasdaq15d
Silexion Therapeutics Announces Promising Preclinical Results for SIL-204 in Enhancing Chemotherapy Efficacy for Pancreatic Cancer
Silexion Therapeutics Corp. announced promising preclinical results for its second-generation RNA interference therapy, SIL-204, which demonstrates synergistic efficacy when used in combination ...
Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International
The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over ...